Premium
SAKK 36/13–IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL
Author(s) -
Novak U.,
Fehr M.,
Zander T.,
Winterhalder R.,
Amram M.,
Stathis A.,
Rondeau S.,
Berardi S.,
Eckhardt K.,
Driessen C.,
Renner C.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_71
Subject(s) - mantle cell lymphoma , ibrutinib , medicine , bortezomib , lenalidomide , proteasome inhibitor , adverse effect , phases of clinical research , oncology , lymphoma , pharmacology , clinical trial , leukemia , multiple myeloma , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom